Skip to content
New
The AI buying guide for BD&L executives — now available on demand
Watch →
Scientific insight
Scientific insights: Why China Now Owns the Late-Stage IL-4R Pipeline
Chinese companies now run seven of the eight IL-4Rα assets in Phase III — and the eighth is licensed to China too, with MG-K10’s latest Phase III data (94.3% EASI-75 at week 52) showing exactly why this comp set can’t be ignored.
The unmet need is real. Even with three approved biologics, roughly half of SLE patients hit a meaningful composite response at one year, and sustained remission is rare. TLR7 sits genetically upstream of the interferon axis that drives ~75% of disease — a clean, well-validated target.
Scientific insight
Scientific insights: TLR7 in lupus- Daiichi Sankyo’s DS-7011a
Daiichi Sankyo’s anti-TLR7 antibody just completed Phase 1b/2 — here’s how VibeOne sees the TLR7/8 landscape in lupus today.
The unmet need is real. Even with three approved biologics, roughly half of SLE patients hit a meaningful composite response at one year, and sustained remission is rare. TLR7 sits genetically upstream of the interferon axis that drives ~75% of disease — a clean, well-validated target.
Scientific insight
Scientific insights: The Integrin α4β7 landscape in IBD
Eli Lilly’s $3.2B acquisition of Morphic put renewed focus on Integrin α4β7 as a target in IBD. In collaboration with Sleuth, we assessed the competitive landscape and key risks for MORF-057—including its differentiation potential as a gut-selective oral therapy.
Scientific insight
Scientific insights: CKD
VibeOne analyzed 100+ CKD programs and found a clear pattern: small molecules dominate and repurposed drugs win. The next kidney breakthrough may already be in a cardiovascular trial.
Scientific insight
Scientific insights:The ActRIIB Challenge (LAE103)
The obesity market is undergoing a quiet revolution: it’s no longer about how much weight patients lose, but what kind of weight they lose.
Scientific insight
Scientific insights: Urea cycle disorders
Drug hunters need to watch Urea Cycle Disorders! Gene therapies (cost) and ERTs (patient experience) still leave much to be desired.
Scientific insight
Scientific insights: Kidney disease
Explore why kidney disease is emerging as a top therapeutic focus. See how VibeOne identifies high-potential kidney indications and guides strategic prioritization.
Scientific insight
Scientific insights: Fabry disease
Fabry disease may seem niche, but it’s becoming a bellwether for how global innovation and modality shifts are reshaping rare disease pipelines.